Healthcare / Medical Instruments & SuppliesShenzhen
$22.43
+0.10 (+0.45%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-6.1M · quality 52.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
20/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.8B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-3.6%
↓Gross Margin
68.4%
↑Debt/Equity
0.18
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+1.8%
FCF CAGR
—
FCF margin
-1.8%
FCF / Net income
0.25x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $342.0M · net income $-24.0M · FCF $-6.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $342.0M | $342.0M | $403.8M | $422.2M | $323.8M |
| Net Income | $-24.0M | $-24.0M | $10.8M | $8.3M | $-76.0M |
| EBITDA | $-1.4M | $-1.4M | $45.3M | $35.3M | $-68.6M |
| EPS | -0.19 | -0.19 | 0.09 | 0.07 | -0.60 |
| Gross Margin | 68.4% | 68.4% | 68.4% | 65.5% | 49.4% |
| Operating Margin | -7.6% | -7.6% | 7.1% | 5.8% | -22.2% |
| Net Margin | -7.0% | -7.0% | 2.7% | 2.0% | -23.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.18 | 0.18 | 0.12 | 0.11 | 0.10 |
| Current Ratio | 2.91 | 2.91 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-6.1M | $-6.1M | $5.5M | $-54.1M | $-48.8M |
| Returns | |||||
| ROE | -3.6% | -3.6% | 1.5% | 1.2% | -11.1% |
| Valuation | |||||
| P/E | — | — | 196.97 | 263.01 | — |
| EV/EBITDA | — | — | 44.37 | 58.10 | — |
| P/B | 4.24 | 4.24 | 3.04 | 3.13 | 3.28 |
| Growth & Yield | |||||
| Revenue Growth | -15.3% | -15.3% | -4.4% | 30.4% | — |
| EPS Growth | -322.4% | -322.4% | 30.4% | 110.9% | — |
| Dividend Yield | 0.3% | 0.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-6.3%
Start / end P/E
n/dx → n/dx
EPS bridge
0.09 → -0.19
Residual
-6.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.